Company Type
Sector
Index
Countries
Reset

Laurent Audoly France

Pierre Fabre Fund for Innovation is a new Open Innovation initiative targeting biotech companies, startups and research laboratories (public or private) specialized in oncology or dermatology, two of the core therapeutic activities of Pierre Fabre R&D group.

Pierre Fabre Fund for Innovation supports R&D projects either within 24 months from reaching clinical development or at early stage of clinical development. The support consists of diverse forms of collaboration: sharing Pierre Fabre’s expertise over the full pharmaceutical value chain, co-financing of the research program, taking minority equity participation or negotiating license agreements.

Website:
http://www.pierre-fabre.com/en/pierre-fabre-fund-innovation
Company Type
Private
Sector
Year Founded
2016
Management Team

Laurent Audoly, Managment partner

Vincent Serrra, Executive Partner

Tony Sedwick, Advisor

Laurent Audoly
Pierre Fabre Fund for Innovation
Senior Vice President, Head of R&D, Managing Partner, Global Head of Drug Development and Translational Medicine 
Biography

Dr. Laurent Audoly is Senior Vice President and heads Research and Development at Fabre Pharmaceuticals for both novel medicines and consumer healthcare products. Laurent is also Managing Partner and Founder of the Pierre Fabre Fund for Innovation. In addition, Laurent is president of the Orphan Diseases and the Medical Devices units within Pierre Fabre.
Prior to this role, Laurent was Chief Scientific Officer in biotech focused on next generation therapeutic proteins where he led the growth of the pipeline from no drug candidates prior to his arrival to a high value pipeline and multiple strategic partnerships with big pharma ultimately leading to a successful exit.
Laurent has held positions of increasing leadership responsibilities in the pharmaceutical industry (Pfizer, Merck, MedImmune) contributing to the identification of new projects and the development of five approved drugs in inflammation, dermatology, cardiovascular diseases, and oncology as well as leading large teams across the pharma value chain.
Throughout his career, he has championed high impact collaborations and established a world-wide network of academic and company-based partnerships. Many of these collaborations have resulted in drug development projects. Laurent is focused on strategic and business growth and has also established strong connections with internal and external commercial and manufacturing organizations. He studied medicine and chemistry for his Bachelor’s degree and graduated with a Ph.D. in Pharmacology from Vanderbilt University. Laurent was awarded a fellowship from the American Heart Association during his post-doctoral training at Duke University. Laurent has maintained strong ties with the academic world as an Associate Professor (Adj) at Duke NUS Graduate Medical School. He has also served on NIH study sections, given seminars at universities across the world, and published > 70 papers and patents. He is on the board and an advisor for multiple healthcare organizations across the world aimed at improving healthcare and accelerating the discovery and advancement of novel therapies for patients and their families.